| イタリア | トルコ | オーストリア | |
| 血漿交換術 | から $2,200 | から $1,200 | から $2,000 |
| 多発性硬化症リハビリテーション | から $4,500 | から $3,000 | から $10,000 |
| 多発性硬化症の薬物療法 | から $5,500 | から $2,500 | から $2,000 |
| オクレリズマブ | から $35,000 | から $10,000 | から $35,000 |
| 血漿交換 | から $2,250 | から $3,900 | - |
Bookimedは多発性硬化症治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。多発性硬化症治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。多発性硬化症治療の旅路でお一人になることはありません。
Italy hosts leading neurology centers recognized globally for multiple sclerosis (MS) care. Top-rated facilities include San Raffaele Hospital and San Donato Hospital in Milan. These institutions hold IRCCS accreditation for combining clinical excellence with advanced research. They rank among the best specialized hospitals globally.
Bookimed Expert Insight: Data shows Milan is the primary hub for MS care. Hospitals like San Raffaele and San Donato serve over 300,000 patients annually. This high volume ensures specialists manage diverse MS cases regularly. Choosing these larger IRCCS centers often provides faster access to the latest disease-modifying therapies. These treatments may reach smaller regional hospitals much later.
Patient Consensus: Patients note that university hospitals in Milan and Rome offer the best specialist access. Many recommend using private consultations to skip long public wait times for initial diagnosis. Traveling from southern regions to northern centers is common to access newer monoclonal antibody treatments.
The latest Disease-Modifying Therapies (DMTs) for multiple sclerosis are available in Italy. The Italian Pharmaceutical Agency (AIFA) authorizes and reimburses high-efficacy treatments. Patients access these therapies through specialized MS centers. Availability includes S1P receptor modulators and monoclonal antibodies like ocrelizumab.
Bookimed Expert Insight: Data shows a clear advantage in seeking treatment at IRCCS-accredited facilities in Milan. San Raffaele and San Donato Hospital both maintain this research designation. These institutions often provide faster access to newer protocols. They serve over 300,000 patients annually and integrate the latest research directly into clinical practice.
Patient Consensus: Patients note it is important to document all disease activity to speed up drug approvals. Those in Northern Italy often report shorter waiting times for receiving their first infusions.
International patients can obtain remote second opinions from leading Italian neurological centers specializing in Multiple Sclerosis. Institutions like San Raffaele Research Hospital in Milan provide virtual consultations via secure platforms. Specialists review clinical history, laboratory reports, and MRI scans to confirm diagnoses or suggest treatment adjustments.
Bookimed Expert Insight: San Raffaele and San Donato share the same Italian Ministry of Health accreditation. Both facilities manage over 300,000 patients annually using high-volume research protocols. This shared infrastructure ensures that even remote consultations benefit from Europe's largest clinical data pools. Choosing either facility provides access to identical quality standards for complex neuro-immunological reviews.
Patient Consensus: Patients note that uploading high-quality MRI scans in advance is the most critical step. They suggest using translation tools for initial outreach to ensure clinical records are understood correctly.
Italy's National Health Service (SSN) provides free or highly subsidized care for Multiple Sclerosis. Patients access specialized centers for diagnosis and monitoring. Disease-modifying therapies (DMTs) are fully covered. The system includes exemptions for specialist visits and diagnostic tests like MRI scans.
Bookimed Expert Insight: Quality of care often correlates with research hospital status. Facilities like San Raffaele and San Donato in Milan hold IRCCS accreditation. This status combines clinical care with advanced research activities. Data shows these northern centers often provide faster access to innovative treatments. This includes protocols like hematopoietic stem cell transplantation (HSCT) for aggressive cases.
Patient Consensus: Patients value the zero-cost access to expensive medications compared to other countries. Many note it is important to prepare for bureaucratic delays when applying for disability pensions.
Therapies including haematopoietic stem cell transplantation (AHSCT) are available at specialised Italian centres. These treatments typically target aggressive forms of multiple sclerosis. Italy maintains strict regulatory oversight through the Ministry of Health and IRCCS-accredited research hospitals.
Bookimed Expert Insight: Italy stands out because its top neurology centres, such as San Raffaele, are IRCCS-certified research hospitals. This means they integrate laboratory breakthroughs directly into clinical practice. Patients often find these academic centres offer earlier access to emerging protocols like Natural Killer cell therapy.
Patient Consensus: Patients in Italy emphasise that options like HSCT require rigorous eligibility checks by specialists. Experience shows that coordinating with local neurologists is essential. This helps manage the extended pre-treatment assessments and follow-up care required.
Italian specialists treat all types of multiple sclerosis. These include relapsing-remitting, secondary progressive, primary progressive, and clinically isolated syndrome. Research hospitals like San Raffaele in Milan use therapies such as Ocrevus and plasmapheresis. They focus on tailored care to manage inflammation and neurological damage.
Bookimed Expert Insight: Italian research hospitals like San Raffaele and San Donato use their IRCCS accreditation to link clinical trials and patient care. This status allows them to offer customised treatments for rare immune conditions. For Australian patients, this means access to specialised protocols like Natural Killer cell therapy. These are often restricted to research settings elsewhere.
Patient Consensus: Patients find that Italian specialists focus heavily on matching the specific MS phenotype to the treatment. This is particularly true for highly active relapsing disease. They often suggest checking a centre's experience with progressive forms before travelling to Italy.
Italy offers holistic rehabilitation for multiple sclerosis through a network of 240 specialised centres. These facilities integrate neurological care with physiotherapy, psychological support, and occupational therapy. Accredited IRCCS hospitals in Milan and Rome provide research-led protocols. These programs aim to improve daily function and mobility.
Bookimed Expert Insight: Italian healthcare uses a strict IRCCS accreditation for research hospitals. Ospedale San Raffaele and San Donato Hospital both hold this status. This means they combine clinical treatment with active scientific research. Patients benefit from earlier access to emerging therapies before they reach standard clinics.
Patient Consensus: Patients note that Italian care focuses heavily on neurological expertise within major accredited hospitals. It is important to treat holistic services as complementary to evidence-based medical treatments.
International patients seeking multiple sclerosis treatment in Italy undergo a structured clinical process. It begins with a remote neurological assessment. Patients submit MRI scans and medical records to centres like San Raffaele in Milan. Local specialists confirm the diagnosis before creating a tailored treatment plan.
Bookimed Expert Insight: Italian research hospitals like San Raffaele and San Donato combine clinical care with active research. They manage over 300,000 patients annually. This high volume allows doctors to develop protocols for rare immune responses. For Australian patients, this means access to specialists who handle complex, treatment-resistant cases daily.
Patient Consensus: Patients note it is essential to bring a complete medication history and radiology reports. Italian centres prioritise a records-heavy intake for treatment continuity once patients return home.